The Osteoprotective Effects Of Kaempferol: The Evidence From In Vivo And In Vitro Studies

Sok Kuan Wong
Kok-Yong Chin
Soelaiman Ima-Nirwana

Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Abstract: Kaempferol is a dietary bioflavonoid ubiquitously found in various types of plant. It possesses a wide range of medicinal properties suggesting its potential clinical utility that requires further investigation. The present review intends to highlight the efficacy of kaempferol and its molecular mechanisms of action in regulating bone metabolism. Many reports have acknowledged the bone-protecting property of kaempferol and kaempferol-containing plants using in vitro and in vivo experimental models. Kaempferol supplementation showed bone-sparing effects in newborn rats, glucocorticoid-induced and ovariectomy-induced osteoporotic models as well as bone fracture models. It achieves the bone-protective effects by inhibiting adipogenesis, inflammation, oxidative stress, osteoclastic autophagy and osteoblastic apoptosis while activating osteoblastic autophagy. The anti-osteoporotic effects of kaempferol are mediated through regulation of estrogen receptor, bone morphogenetic protein-2 (BMP-2), nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) signaling pathways. In summary, kaempferol exhibits beneficial effects on skeleton, thus is potentially effective for the prophylaxis and treatment of osteoporosis.

Keywords: bone, flavonoid, fracture, osteoblast, osteoclast, osteoporosis

Introduction

Osteoporosis is a degenerative bone disorder characterized by deterioration of bone microstructure resulting from excessive bone resorption and declining bone formation. It is a multifactorial disease, whereby aging, sex hormone deficiency, medication use, alcoholism, nicotine and medical conditions (such as diabetes, hypertension, dyslipidemia and metabolic syndrome) can initiate and exacerbate progression of bone loss. The choices of medications for osteoporosis include bisphosphonates, teriparatide, receptor activator of nuclear factor-kappa-β ligand (RANKL) inhibitors (denosumab) and selective estrogen receptor modulators (SERMs). These therapies are effective to prevent further bone loss and fractures but they are accompanied by undesirable side effects and cost issues. The discovery of natural products with potential bone-protecting effects might offer alternative treatment agents to overcome the drawbacks of conventional therapies. Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) and its derivatives are natural flavonoids contributing to the nutritional qualities of fruits and vegetables. It is also present in botanic plants commonly used as traditional medicines, such as Ginkgo biloba, Moringa oleifera and propolis. Kaempferol is referred to as a...
nutraceutical due to its various health benefits previously proven scientifically, which include cardioprotective, neuroprotective, anxiolytic, analgesic, anti-allergic, anti-platelet aggregation, anti-cancer, anti-microbial, anti-obesity, anti-hyperglycemic, anti-hypertensive, anti-hyperlipidemic, anti-aging, anti-oxidative, anti-inflammatory and anti-osteoporotic effects [reviewed by Calderon-Montano et al18 and Imran et al19]. Some of the medicinal properties of kaempferol are directly associated with its bone-sparing effects, which will be reviewed in the following discourse.

This review article aims to provide the in vivo and in vitro experimental evidence surrounding the efficacy of kaempferol in preventing bone loss. This review also discusses the mechanisms of action of kaempferol and its potential as a therapeutic agent for the treatment of osteoporosis.

**Literature Search**

Literature search was performed using PubMed and Medline databases from June 1, 2019 to June 30, 2019, using the string “kaempferol AND (bone OR osteoporosis OR fracture OR osteoblast OR osteoclast)”. Only original research articles written in English, published since the inception of the databases until June 30, 2019, were included. The titles and abstracts were screened, and full texts of the relevant articles were retrieved.

**In Vivo Studies On The Effects Of Kaempferol On Bone**

The bone-sparing action of kaempferol in animals has been identified (Table 1). Using newborn Sprague-Dawley rats as an animal model, 5 µM kaempferol was injected into the top of the periosteum of the parietal bones for 12 days. Histological analysis of parietal bones showed that calcification at the area of new bone formation was increased. Immunostaining with bone sialoprotein (BSP), osterix (OSX) and Runx-related transcription factor 2 (Runx-2) antibodies showed that the expression of these proteins was enhanced by kaempferol treatment. The bone area and number of osteoblasts were significantly increased in the kaempferol-treated group compared to the vehicle-treated control group. Osteoblasts have angular-shaped cytoplasm with nuclear polarity, reiterating that the osteoblasts were in the state of active osteoblast differentiation.20 Several other studies investigated the anti-osteoporotic effects of kaempferol using an animal model of bone loss caused by estrogen deficiency, whereby the animals were bilaterally ovariectomized (OVX) to mimic postmenopausal osteoporosis in elderly women. Trivedi and co-authors found that kaempferol at 5 mg/kg prevented trabecular bone loss in the whole femur, femoral neck of the femur, proximal tibia, the whole vertebra and L3 vertebra. The compression test indicated that L3 vertebrae of the kaempferol-treated animals required more compressive energy than the negative controls. Kaempferol also inhibited bone turnover by lowering the serum alkaline phosphatase (ALP) in the OVX rats. The bone marrow cells derived from the kaempferol-supplemented OVX group had higher mineralized nodules but lower adipocytes compared to the vehicle-supplemented OVX group.21 A recent study demonstrated that oral administration of kaempferol (5 mg/kg) for 8 weeks increased femoral bone mineral density (BMD) and Young’s modulus of elasticity but decreased osteocalcin (OCN) and RANKL in OVX rats. Histologically, the OVX rats receiving kaempferol had higher bone volume/total volume (BV/TV), trabecular bone area (B.Ar), trabecular bone perimeter (B.Pm) and bone surface/total volume (BS/TV) relative to the negative control animals.22 Kaempferitrin, another name for kaempferol-3,7-dirhamnoside, at the dose of 8 or 16 mg/kg had been shown to increase BMD, bone mineral content (BMC), tissue mineral content, tissue mineral density, bone volume fraction, trabecular number (Tb.N), connectivity density (Conn.D) and decrease trabecular separation (Tb.Sp) in the OVX rats. Kaempferitrin also influenced the levels of bone formation and resorption markers, whereby a higher level of ALP, as well as lower levels of cathepsin K and tartrate-resistant acid phosphatase (TRAP), were observed after the treatment.23 Apart from the surgical-castrated animal model, Adhikary et al used corticosteroid-induced osteoporotic and fractured animals to explore the osteoprotective and bone healing properties of kaempferol, respectively. Methylprednisolone (a corticosteroid hormone) was injected subcutaneously (s.c.) into female Sprague-Dawley rats to induce bone loss. The animals receiving kaempferol (5 mg/kg) for four weeks had higher BV/TV, BS/TV, Tb.N, Conn.D as well as lower Tb.Sp and structure model index (SMI) at the proximal tibial metaphyseal region than the animals without treatment of kaempferol. Examination of the cortical bones revealed that higher cross-sectional thickness (Cs.Th), mean polar moment of inertia (MMI), B.Pm and tissue perimeter (T.Pm) was detected at tibial diaphyseal region in the kaempferol-treated group. Oral administration of kaempferol also increased BMD, bone strength, bone formation-related genes [Runx-2, OSX, ALP, OCN, collagen type I (COL1), bone morphogenetic protein-2 (BMP-2) and osteoprotegerin (OPG)], as well as decreasing bone resorption-related gene
Table 1: In Vivo Studies On The Bone-Protecting Properties Of Kaempferol

<table>
<thead>
<tr>
<th>Animal Strain</th>
<th>Experimental Groups</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn Sprague-Dawley rats</td>
<td>Control, Kaempferol (5 μM, injected into the top of the periosteum of the parietal bone)</td>
<td>Compared to normal group, treatment with kaempferol:</td>
<td>Yang et al (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BSP, OSX and Runx-2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ bone area and number of osteoblasts</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ osteoblast differentiation</td>
<td></td>
</tr>
<tr>
<td>Female Sprague-Dawley rats (n=10/group)</td>
<td>Sham, O VX, O VX + kaempferol (5 mg/kg, oral)</td>
<td>Compared to OVX group, treatment with kaempferol:</td>
<td>Trivedi et al (2008)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BMD in total femur, femoral neck, proximal tibia, total vertebra and L3 vertebra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ compressive energy for L3 vertebra and ↓ ALP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ mineralization and ↓ adipogenesis in bone marrow cells</td>
<td></td>
</tr>
<tr>
<td>Female Wistar rats (n=8/group)</td>
<td>Sham, O VX, O VX + kaempferol (5 mg/kg, oral)</td>
<td>Compared to OVX group, treatment with kaempferol:</td>
<td>Nowak et al (2017)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BMD and Young's modulus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↓ O CN and RANKL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BV/TV, B.Ar, B.Pm and BS/TV</td>
<td></td>
</tr>
<tr>
<td>Female Sprague-Dawley rats (n=8/group)</td>
<td>Sham, O VX, O VX + estradiol valerate (1 mg/kg, oral), O VX + kaempferitrin (8 mg/kg, oral), O VX + kaempferitrin (16 mg/kg, oral)</td>
<td>Compared to OVX group, treatment with kaempferitrin:</td>
<td>Ma et al (2015)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BMD, BMC, tissue mineral content, tissue mineral density, bone volume fraction, Tb. N, Conn.D and ↓ Tb.Sp</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ ALP, ↓ cathepsin K and TRAP</td>
<td></td>
</tr>
<tr>
<td>Female Sprague-Dawley rats (n=10/group)</td>
<td>Normal, Methylprednisolone (5 mg/kg, s.c.), Methylprednisolone (5 mg/kg, s.c.) + kaempferol (5 mg/kg, oral), Methylprednisolone (5 mg/kg, s.c.) + human 1–34 PTH (5 μg/kg, 5 times/week, s.c.)</td>
<td>Compared to methylprednisolone-treated group, treatment with kaempferol:</td>
<td>Adhikary et al (2018)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BV/TV, BS/TV, Tb.N, Conn.D, ↓ Tb.Sp and SMI of proximal tibial metaphyseal region</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ Cs.Th, MMI, B.Pm and T.Pm of tibial diaphyseal region</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BMD of femur and tibia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BFR, MAR and MS of femur diaphysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ energy to failure and stiffness of femur diaphysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ PINP and ↓ CTX-1 in serum</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ Runx-2, OSX, ALP, OCN, COL1, BMP-2, OPG and ↓ RANKL in bone tissue</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ nodule formation and ALP activity</td>
<td></td>
</tr>
<tr>
<td>Female Sprague-Dawley rats (n=10/group)</td>
<td>Fracture (drill bit of diameter 0.8 mm in the anterior portion of the femur diaphysis), Fracture + kaempferol (5 mg/kg, oral), Fracture + Methylprednisolone (5 mg/kg, s.c), Fracture + Methylprednisolone (5 mg/kg, s.c.) + kaempferol (5 mg/kg, oral)</td>
<td>Compared to fracture + methylprednisolone group, treatment with kaempferol:</td>
<td>Adhikary et al (2018)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ BV/TV, Tb.Th, Tb.N, Conn.D, ↓ SMI and DA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ↑ calcein intensity, BMP-2, BMP-4, COL1</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table I (Continued).

<table>
<thead>
<tr>
<th>Animal Strain</th>
<th>Experimental Groups</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male ICR mice (n=5/group)</td>
<td>• Sham</td>
<td>Compared to fracture group, treatment with kaempferol:</td>
<td>Nguyen et al25 (2016)</td>
</tr>
<tr>
<td></td>
<td>• Fracture</td>
<td>• ↑ callus diameter</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fracture + kaempferol (0.2 mg/kg, oral)</td>
<td>• ↑ new bone formation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fracture + kaempferol (0.5 mg/kg, oral)</td>
<td>• ↑ endochondral ossification</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fracture + kaempferol (5 mg/kg, oral)</td>
<td>• ↑ density and size of callus</td>
<td></td>
</tr>
<tr>
<td>Male ICR mice (n=5/group)</td>
<td>• Sham</td>
<td>Compared to fracture group, treatment with kaempferol:</td>
<td>Kim et al26 (2014)</td>
</tr>
<tr>
<td></td>
<td>• Fracture</td>
<td>• ↑ ultimate force and fracture energy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fracture + kaempferol (0.2 mg/kg, oral)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Sprague–Dawley rats (n=6/group)</td>
<td>• Sham</td>
<td>Compared to OVX group, treatment with kaempferol and formulated kaempferol (layer-by-layer matrix):</td>
<td>Gupta et al27 (2013)</td>
</tr>
<tr>
<td></td>
<td>• OVX</td>
<td>• ↑ BMD at whole femur, femur diaphysis, proximal tibia and vertebral region</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX + kaempferol (1 mg/kg, oral)</td>
<td>• ↑ femoral stiffness and mineralization of osteoblasts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX + formulated kaempferol (layer-by-layer matrix) (1 mg/kg, oral)</td>
<td>Compared to kaempferol group, treatment with formulated kaempferol (layer-by-layer matrix):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sham</td>
<td>• ↑ BMD at whole femur, femur diaphysis, proximal tibia and vertebral region</td>
<td></td>
</tr>
<tr>
<td>Female Sprague–Dawley rats (n=12/group)</td>
<td>• Sham</td>
<td>• ↑ femoral stiffness and mineralization of osteoblasts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX + kaempferol (5 mg/kg, oral)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX + formulated kaempferol (layer-by-layer matrix) (5 mg/kg, oral)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• OVX + PTH (20 μg/kg, s.c.)</td>
<td>Compared to OVX group, treatment with kaempferol and formulated kaempferol (layer-by-layer matrix):</td>
<td>Kumar et al28 (2012)</td>
</tr>
<tr>
<td>Female Sprague–Dawley rats (n=5/group)</td>
<td>• Control</td>
<td>• ↑ MAR and BFR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↑ BV/TV, Tb.N, Tb.Th, ↓ Tb.Sp and SMI at L5 vertebra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↓ OCN and CTX</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Compared to kaempferol group, treatment with formulated kaempferol (layer-by-layer matrix):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↑ MAR and BFR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↑ BV/TV, Tb.Th and ↓ SMI at tibial proximal metaphysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↑ BV/TV, Tb.N, Tb.Th, ↓ Tb.Sp and SMI at L5 vertebra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ↓ OCN</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ALP, alkaline phosphatase; B.Ar, bone area; BFR, bone formation rate; BMC, bone mineral content; BMD, bone mineral density; BMP-2, bone morphogenetic protein-2; BMP-4, bone morphogenetic protein-4; B.Pm, bone perimeter; BSP, bone sialoprotein; BS/TV, bone surface/total volume; BV/TV, bone volume/total volume; COL1, collagen type I; Conn.D, connectivity density; Cs.Th, cross-sectional thickness; CTX-1, C-telopeptide of type I collagen; DA, degree of anisotropy; MAR, mineral apposition rate; MMI, mean polar moment of inertia; MS, mineralizing surface; OCN, osteocalcin; OPG, osteoprotegerin; OSX, osterix; OVX, ovariectomized; P1NP, procollagen type I N-terminal propeptide; RANKL, receptor activator of nuclear factor kappa-B ligand; Runx-2, Runt-related transcription factor 2; s.c., subcutaneous; SMI, structure model index; Tb.N, trabecular number; Tb.Sp, trabecular separation; T.Pm, tissue perimeter; TRAP, tartrate-resistant acid phosphatase.
In Vitro Studies And Mechanism Of Action Of Kaempferol As A Bone-Protecting Agent

A wide array of laboratory studies investigated the direct effects of kaempferol on osteoblastic cells or osteoblastic precursor cells (Table 2). Kaempferol did not show any cytotoxic effect on bone marrow-derived mesenchymal stem cells (MSCs) at the concentration up to 100 μM. Kaempferol, extracted from Polygonum tinctorium, stimulated the differentiation and mineralization of murine pre-osteoblastic MC3T3-E1 cells, as seen by augmentation of ALP activity and calcification. Osteoblast-like UMR-106 cells treated with kaempferol had significantly higher expression of Runx-2, OSX and BSP. The presence of kaempferol also resulted in increased calcium content in the rat femoral diaphyseal and metaphyseal tissue culture. Apart from that, stimulation of kaempferol-immobilized TiO₂ in rat bone marrow stromal cell culture promoted ALP activity, calcium deposition and osteoblast differentiation-related genes such as Runx-2, OCN, osteonectin and osteopontin (OPN).

In an in vitro study, mature osteoclasts were generated from osteoclast precursors (such as monocyte/macrophage cells and bone marrow cells) in the presence of macrophage-colony stimulating factor (M-CSF) and RANKL. Several in vitro studies showed the anti-osteoclastogenic effects of kaempferol (Table 2). In murine macrophage RAW264.7 cells treated with RANKL, kaempferol was shown to abrogate RANKL-induced formation of TRAP-positive multinucleated cells and resorption pits, which are the indicator for osteoclast differentiation. The downregulation of osteoclastogenic factors including RANKL, Fos proto-oncogene (c-Fos), nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and tumor necrosis factor receptor-associated factor 6 (TRAF6) were also observed in kaempferol-treated cells. Other in vitro studies were
Table 2 In Vitro Studies On The Bone-Protecting Properties Of Kaempferol

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
</table>
| Rat calvarial osteoblasts treated with dexamethasone | Kaempferol (5 μM) | • ↑ viability and proliferation of osteoblast  
• ↓ apoptotic cells  
• ↑ ALP, Runx-2, OSX, COL1, OCN, BMP-2  
• ↑ Bcl2; ↓ Bax  
• ↑ phosphorylation of SMAD1/5/8 and ERK | Adhikary et al\(^{24}\) (2018) |
| Rat primary osteoblasts | Kaempferol (10 μM) | • ↑ ALP, Runx-2, OSX, COL1, OCN, osteonectin  
• ↑ mineralization of osteoblasts  
• ↑ phosphorylation of ERα (ERα activation) | Guo et al\(^{50}\) (2012) |
| Rat calvarial osteoblasts | Kaempferol (5 μM) | • ↑ ALP and formation of mineralized nodules  
• ↑ cytokeratin-14, HSP70, ↓ aldose reductase, caldesmon | Kumar et al\(^{99}\) (2010) |
| Rat calvarial osteoblasts | Kaempferol (5 μM) | • ↑ OCN and COLI levels  
• ↑ mineralization and fiber density  
• ↑ gene and protein expression of cytokeratin-14  
• ↓ p-AMPK and activate mTORC1 complex | Khedgikar et al\(^{100}\) (2016) |
| Rat calvarial osteoblasts and bone marrow cells | Kaempferol (0.2–5 μM) | • ↑ calcified nodules and calcium deposition  
• ↓ differentiation of bone marrow cells to adipocytes | Trivedi et al\(^{21}\) (2008) |
| Rat bone marrow stromal cells | Kaempferol-immobilized titanium dioxide (50 μg/100% ethanol) | • ↑ ALP activity and calcium deposition  
• ↑ Runx-2, OCN, osteonectin, OPN | Tsuchiya et al\(^{29}\) (2018) |
| Pre-osteoblastic MC3T3-E1 cells | Kaempferol (2–20 μM) | • ↑ ALP, Runx-2, OSX, OCN → ↑ osteoblast differentiation  
• ↓ PPAR-γ → ↓ adipocyte differentiation | Byun et al\(^{44}\) (2012) |
| Pre-osteoblastic MC3T3-E1 cells | Kaempferol (10–20 μM) | • ↑ ALP, calcium deposition (mineralization) | Miyake et al\(^{31}\) (2003) |
| Pre-osteoblastic MC3T3-E1 cells treated with TNF-α | Kaempferol (10 μM) | • ↓ IL-6 and MCP-1  
• ↓ NF-κB activation | Pang et al\(^{34}\) (2006) |
| Pre-osteoblastic MC3T3-E1 cells treated with dRb | Kaempferol (0.1–10 μM) | • ↑ OPG, collagen content and mineralization in the cells  
• ↑ OPG and ↓ MDA | Suh et al\(^{79}\) (2009) |
| Pre-osteoblastic MC3T3-E1 cells | Kaempferol (10 μM) | • ↑ ALP, Runx-2, OSX, COL1, BMP-2  
• ↑ beclin-1, SQSTM1/p62 and LC3 | Kim et al\(^{35}\) (2016) |
| Pre-osteoblastic MC3T3-E1 cells incubated with opossum kidney cells | Kaempferol (70 nmol/L) | • ↑ cell growth and osteoblast growth factor  
• ↑ level of BMPRII | Long et al\(^{57}\) (2014) |

(Continued)
<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
</table>
| Pre-osteoblastic MC3T3-E1 cells   | 8-prenylkaempferol (1–20 μM) | • ↑ ALP, COL1, OCN, OPN  
• ↑ bone nodule formation  
• ↑ BMP-2, Runx-2, p-SMAD1/5/8 and p-p38 | Chiou et al.²⁶ (2011) |
| LPS-treated rabbit bone marrow-derived MSCs | Kaempferol (100 μM) | • ↑ MSCs differentiation  
• ↓ MSCs apoptosis  
• ↑ expression of Ki-67 and PCNA  
• ↑ SOX-9, COL2, aggregcan  
• ↓ MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5  
• ↑ CPT-1, PPAR-α and ACC  
• ↓ SREBP-1c, FAS and PPAR-γ  
• ↓ Oil Red O-positive droplets  
• ↓ TNF-α, IL-1β, IL-6, iNOS and NF-κB; ↑ IL-10 | Zhu et al.³⁰ (2017) |
| Human osteoblastic MG-63 cells     | Kaempferol (50 μM) | • ↑ ALP  
• ↑ activation of ERκ and estrogen receptor | Prouillet et al.³⁵ (2004) |
| Human osteoblastic MG-63 cells     | Kaempferol (1 μM)  | • ↑ activation of ERβ-mediated ERE-reporter transcription | Tang et al.³¹ (2008) |
| Osteoblast-like UMR-106 cells      | Kaempferol (5 μM)  | • ↑ Runx-2, OSX, BSP | Yang et al.³² (2010) |
| Osteoblast-like UMR-106 cells      | Kaempferol (5–10 μM) | • ↑ ALP  
• Activated ERα- and ERβ-mediated ERE transcription  
• Activated AP-1 reporter expression | Yang et al.³³ (2011) |
| Rat femoral-diaphyseal or metaphyseal tissues | Kaempferol (0.1–1 μM) | • ↑ calcium content | Yasmaguchi et al.³⁴ (2007) |
| Murine macrophage RAW264.7 cells treated with RANKL | Kaempferol (10 μM) | • ↓ RANKL-induced c-Fos expression and osteoclastogenesis | Pang et al.³⁶ (2006) |
| Murine macrophage RAW264.7 cells treated with RANKL | Kaempferol (50 μM) | • ↓ TRAP-positive cells and resorption pits  
• ↓ RANKL, TRAF6, c-Fos, NFATc1  
• ↓ p-ERK and p-JNK  
• ↓ bedin-1 and SQSTM1/p62 | Kim et al.³⁷ (2018) |
| Bone marrow cells treated with M-CSF, RANKL and IL-1β | Kaempferol (50–200 μM) | • ↓ TRAP-positive cells and resorption pits  
• ↓ survival of osteoclast precursor cells  
• ↓ c-Fos and NFATc1  
• ↓ ERK, p38 and JNK | Lee et al.³⁸ (2014) |
Table 2 (Continued).

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
</table>
| LPS-induced murine macrophage RAW264.7 cells  | Resokaempferol (12.5–50 μM)           | • ↓ NO production  
• ↓ IL-1β, TNF-α, MCP-1, PGE2, iNOS and COX-2  
• ↓ IL-6, p-JAK2 and p-STAT3  
• ↓ expression of IFN-γ and STAT-1 phosphorylation  
• ↓ expression of p-IKK, p-IκB and p-NF-κB  
• ↓ p-JNK and p-p38 | Yu et al (2016) |
| LPS-induced murine macrophage RAW264.7 cells  | Kaempferol 7-O-β-D-glucoside (25–100 μM) | • ↓ NO, PGE2, TNF-α, IL-1β and IL-6  
• ↓ iNOS and COX-2  
• ↓ phosphorylation and degradation of IκBα and IKK-α/β  
• ↓ nuclear localization of the p65 NF-κB  
• ↓ binding activity of AP-1, c-Fos and ERK activation  
• ↓ phosphorylation of STAT1 and STAT3  
• ↓ activation of JAK1 and JAK2 | Lee et al (2018) |
| Highly purified rabbit osteoclasts            | Kaempferol (0.1–100 μM)              | • ↓ pit area (bone resorption), hydroxylysylpyridolinoline content  
• ↑ apoptotic osteoclasts  
• ↓ ROS production | Wattel et al (2003) |

Abbreviations: ACC, acetyl coenzyme A carboxylase; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; ALP, alkaline phosphatase; AMPK, adenosine monophosphate-activated protein kinase; AP-1, activator protein 1; Bax, bcl-2-like protein 4; Bcl2, B-cell lymphoma 2; BMP-2, bone morphogenetic protein-2; BMPRII, bone morphogenetic protein receptor II; BSEP, bone soluble protein; c-Fos, Fos proto-oncogene; COL1, collagen type I; COL1a1, collagen type 1 alpha 1; COL2, collagen type 2; COX-2, cyclooxygenase-2; CPT-1, carnitine palmitoyl transferase-1; ERα, estrogen receptor-alpha; ERβ, estrogen receptor-beta; ERE, estrogen responsive elements; ERK, extracellular-regulated kinase; FAS, fatty acid synthase; HSP70, heat shock protein 70; IκBα, interferon-gamma; IκB, IκB kinase; IL, interleukin; iNOS, inducible nitric oxide synthase; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; MCP-1, monocyte chemoattractant protein; MDA, malondialdehyde; MMP, matrix metalloproteinase; MSCs, mesenchymal stem cells; mTORC1, mammalian target of rapamycin complex 1; NFATc1, nuclear factor of activated T-cells cytoplasmic 1; NF-κB, nuclear factor-kappa B; NO, nitric oxide; OCN, osteocalcin; OPR, osteoprotegerin; OPN, osteopontin; OSX, osteric; PCNA, proliferating cell nuclear antigen; PGE2, prostaglandin E2; PPAR-α, peroxisome proliferator-activated receptor-alpha; PPAR-γ, peroxisome proliferator-activated receptor-gamma; RANKL, receptor activator of nuclear factor kappa-B ligand; ROS, reactive oxygen species; Runx-2, Run-related transcription factor 2; SMAD, suppressor of mothers against decapentaplegic; SOX-9, SRY-box 9; SQSTM1, sequestosome-1; SREBP-1c, sterol regulatory element-binding proteins-1c; STAT, signal transducer and activator of transcription; TNF-α, tumor necrosis factor-alpha; TRAF6, tumor necrosis factor receptor-associated factor 6; TRAP, tartrate-resistant acid phosphatase.
performed to illustrate the mechanisms of action of kaempferol as a potential anti-osteoporotic agent.

**Effects Of Kaempferol On The Fate Of Mesenchymal Stem Cells**

Bone is formed through the endochondral (for long, short and irregular bones) and intramembranous ossification (for flat bones). During endochondral ossification, MSCs differentiate into chondrocytes forming the cartilage matrix and followed by gradual substitution by the bone. Meanwhile, intramembranous ossification is a process of direct differentiation of MSCs into osteoblasts. Matrix metalloproteinases (MMPs) are highly expressed in bone and cartilage and appear to have a role in endochondral ossification during bone modeling and remodeling. MMPs are proteolytic enzymes driving extracellular matrix (ECM) remodeling, chondrocyte proliferation and differentiation, osteoblast, osteoclast and osteocyte viability and function. Matrix metalloproteinases can be categorized into several subgroups according to their substrate preference. Collagenases (MMP-1, MMP-8, MMP-13 and MMP-18) degrade COL1, collagen type 2 (COL2) and collagen type 3 (COL3). Gelatinases (MMP-2, MMP-9) degrade gelatin and other ECM proteins such as laminin and aggrecan. Stromelysins (MMP-3, MMP-10 and MMP-11) cleave non-collagen molecules in the ECM. In addition, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) are also aggrecanases and proteoglycanases that control the structure and function of ECM. Hence, the alteration of MMP and ADAMTS level determines the quality and quantity of bone.

Mesenchymal stem cells are progenitor cells capable of equally differentiating into multiple cell lineages, including adipocytes, osteoblasts and chondrocytes under physiological condition. Hence, they are reciprocally regulated during pathological conditions. The tendency of MSCs differentiation into adipocytes rather than osteoblasts and chondrocytes results in the progression of osteoporosis, thereby suggesting the possible association between obesity-related conditions and bone loss. In a state of over-nutrition, the underlying mechanisms include: (1) the downregulation of peroxisome proliferator-activated receptor-alpha (PPAR-α) suppresses the expression of carnitine palmitoyl transferase-1 (CPT-1, an enzyme that facilitates in the β-oxidation of long-chain fatty acids); (2) the upregulation of sterol regulatory element-binding proteins-1c (SREBP-1c) increases fatty acid synthase (FAS) and acetyl coenzyme A carboxylase (ACC), resulting in fatty acid synthesis and reduced capacity in fatty acid oxidation; (3) the upregulation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) increases the production of lipoprotein lipase (LPL) to hydrolyze triglycerides to two free fatty acids and one monoglycerol molecule.

Kaempferol has a role in modulating these transcription factors that guide MSCs to commit to the osteoblastic and chondrogenic lineage. Increased osteoblast mineralization and calcium deposition but decreased adipocyte differentiation and lipid accumulation were detected in bone marrow cells after kaempferol stimulation. Kaempferol promoted the differentiation of MSCs into osteoblasts by enhancing the expression of ALP, Runx-2, OSX and OCN but inhibited the differentiation of MSCs into adipocyte by downregulating PPAR-γ. In another in vitro study using lipopolysaccharides (LPS)-treated rabbit bone marrow-derived MSCs, kaempferol promoted cell viability and decreased apoptosis. The expression of Ki-67 protein (a mitosis-associated nuclear antigen) and proliferating cell nuclear antigen (PCNA) was found underexpressed in LPS-treated cells and returned to normal after kaempferol treatment. Concomitantly, kaempferol promoted osteogenesis through suppressing matrix degradation. The increase in levels of chondrogenic markers [SRY-Box 9 (SOX-9), COL2 and aggrecan] and the decrease in levels of matrix-degrading enzymes (MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5) were observed. Kaempferol also stimulated the expression of lipid catabolism-related genes (CPT-1 and PPAR-α) while suppressed the expression of lipid anabolism-related genes (SREBP-1c, FAS, ACC and PPAR-γ).
70 (HSP70) to form estrogen receptor dimer. Subsequently, the dimer translocates into the nucleus and binds directly to a specific estrogen-responsive elements (ERE) sequence to enhance its transcriptional response. Apart from that, the non-genomic action of estrogen-estrogen receptor complex may be mediated through the activation of downstream signaling molecules including phosphoinositide 3-kinases (PI3K)/protein kinase B (Akt), mitogen-activated protein kinase (MAPK) and protein kinase C (PKC). The activation of estrogen receptor signaling, whether through classical or non-classical pathways, leads to the suppression of osteoclast differentiation, inhibition of osteoclastic apoptosis, repression of inflammatory cytokines and induction of osteoclastic apoptosis. 

In vivo studies also showed that kaempferol exerted potential in counteracting the adverse effects of estrogen depletion on the skeleton. An earlier in vitro study demonstrated that kaempferol increased ALP activity in MG-63 osteoblasts, but this activity was reduced after treatment with extracellular-regulated kinase (ERK) pathway inhibitor and estrogen receptor antagonist. These findings suggested that the increase of ALP activity by kaempferol was due to activation of ERK, which was the downstream target of estrogen receptor activation. Several in vitro studies were performed to examine the effects of kaempferol on ERα or ERβ activation of ERE gene transcription. Kaempferol was shown to induce luciferase activity in osteoblasts expressing ERE, ERα phosphorylation, ALP activity, bone differentiation markers (Runx-2, OSX, COL1, OCN and osteonectin) and osteoblastic mineralization. Another study by Tang et al. confirmed that kaempferol activated ERβ-mediated ERE-reporter transcription in MG-63 osteoblasts. In accordance with former results, kaempferol isolated from Cuscuta chinensis raised ALP activity in osteblast-like UMR cells as well as activating both ERα- and ERβ-mediated ERE gene transcription.

Effects Of Kaempferol In BMP-2 Signaling Pathway
Bone morphogenetic protein-2 is a member of transforming growth factor-beta (TGF-β) superfamily. It functions to regulate the differentiation of MSCs during skeletal development, bone formation and bone homeostasis by binding to its tetrameric receptor complex. The binding of BMP-2 to its receptor transduces signal via the suppressor of mothers against decapentaplegic (SMAD)-dependent and non-canonical SMAD-independent (p38 MAPK) signaling. The SMAD-dependent signaling involves the formation of SMAD1/5/8-SMAD4 complex which induces the expression of Runx-2. In addition, Runx-2 can be phosphorylated and activated by BMP-2-induced p38 MAPK activation. Thus, Runx-2 is a transcription factor that acts as the center of convergence for the SMAD and p38 MAPK signaling pathways to orchestrate the amplification of its own gene activation and the expression of other osteogenic factors leading to osteoblastogenesis.

Adhikary et al reported that the osteogenic action of kaempferol was attributable to the upregulation of BMP-2 and sustained phosphorylation of SMAD1/5/8. The activation of SMAD1/5/8 via BMP-2 signaling caused by kaempferol treatment resulted in stimulated osteoblast proliferation, exhibited by the high expression levels of ALP, Runx-2, OSX, COL1 and OCN in dexamethasone-induced rat calvarial osteoblasts. Similarly, kaempferol upregulated the expression of BMP-2 along with other osteoblast-activated factors (ALP, Runx-2, OSX and COL1) in preosteoblastic MC3T3-E1 cells. 8-prenylkaempferol, isolated from Sophora flavescens, accelerated ALP activity, osteogenic markers (OCN, OPN, COL1 and Runx-2) expression as well as bone nodules formation. This improvement was associated with increased BMP-2 expression that subsequently caused phosphorylation of SMAD1/5/8 and p38 MAPK. Treatment with noggin (a BMP-2 antagonist) blocked BMP-2-induced ALP activity, phosphorylation of SMAD1/5/8 and p38, thus suggesting that BMP-2 signaling was implicated in the osteogenic action of 8-prenylkaempferol. Apart from the protecting action of BMP-2 produced in osteoblasts, bone morphogenetic protein receptor II (BMPR II) was identified in opossum kidney cells. The authors found that kaempferol increased cell growth, secretion of osteoblast growth factor and level of BMPR II in opossum kidney cells. Findings from this study implied that kaempferol stimulated kidney repair which indirectly stimulates bone formation.

Effects Of Kaempferol In Inflammation
Inflammation is closely relevant to bone loss as numerous inflammatory cytokines are recognized to inhibit osteoblastogenesis and stimulate osteoclastogenesis. Tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), apart from their direct role in promoting osteoclastogenesis and bone resorption, also stimulate osteoblasts to release other bone-resorbing cytokines such as interleukin-
6 (IL-6) and monocyte chemoattractant protein (MCP-1). The amplification of inflammatory response increases the inhibitory effect on osteoblast activities and stimulatory effect on osteoclast activities. Specifically, these cytokines suppressed ALP activity, gene expression for ALP, Runx-2, OSX, osteonectin and OPN. The underlying mechanisms of inflammatory bone loss are mediated partly through (a) the upregulation of sclerostin (SOST) and Dickkopf-related protein 1 (DKK-1) that inhibits the canonical Wnt/Frizzled/β-catenin pathway, (b) the activation of nuclear factor-kappa B (NF-kB), as well as (c) the activation of signal transducers and activators of transcription (STAT), which in turn inhibits MAPK activities. These events subsequently contribute to reduced expression of osteogenic factors (such as Runx-2, OSX, COL1α1, ALP, OCN, OPG and BMP-2) and elevated expression of osteoclastogenic factors (such as RANKL) in osteoblasts.

The ratio of OPG and RANKL determines the fate of osteoclast precursors, whether osteoclastogenesis is promoted or inhibited. The expression of OPG and RANKL is sensitive to inflammatory cytokines. The imbalance in inflammatory response, characterized by the increase in pro-inflammatory cytokines and the decrease in anti-inflammatory cytokines, directs the inhibition of OPG and release of RANKL by osteoblasts to stimulate osteoclast differentiation and bone resorption. The binding of RANKL to RANK on the surface of osteoclast recruits the key downstream adaptor protein TRAF6. Multiple essential signaling pathways are further activated including the MAPK, NF-kB, NFATc1 and PI3K/Akt which ultimately lead to osteoclastogenesis and bone resorption. On the other hand, OPG competitively binds to RANKL, thus blocking the interaction with RANK and preventing excessive bone resorption.

Nitric oxide (NO) is an important multifunctional signaling molecule regulating both physiological and pathological conditions in bone. It appears to exert biphasic effects by affecting the bone formation and resorption processes in osteoblasts and osteoclasts. Bone formation is enhanced while bone resorption is suppressed in low concentration of NO and vice versa. Inducible nitric oxide synthase (iNOS) is one of the three isoforms of NO synthase catalyzing the production of NO from L-arginine. iNOS can be expressed to produce large quantities of NO in response to lipopolysaccharide and pro-inflammatory cytokines. Using murine macrophage RAW264.7 cells, RANKL triggers NO production and iNOS expression through NF-κB activation thereby enhancing osteoclast formation. In vivo studies showed that wild-type C57BL/6 mice with iNOS genotype resulted in bone depletion (decreased bone volume and bone formation) after ovariectomy. Conversely, bone loss did not occur in iNOS-knockout mice and wild-type mice treated with iNOS inhibitor.

Kaempferol potentially protects the bone through its anti-inflammatory property on osteoblastic cells. The inhibitory effect of kaempferol on LPS-induced inflammation in rabbit bone marrow-derived MSCs was reported, whereby the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, iNOS and MCP-1) declined and level of anti-inflammatory cytokine [interleukin-10 (IL-10)] elevated via inhibition of NF-kB nuclear translocation. Congruent with these findings, kaempferol also inhibited the secretion of IL-6, MCP-1 and activation of NF-κB in TNF-α-induced MC3T3-E1 cells. Inflammatory markers have been shown to further stimulate osteoclastogenesis. Addition of IL-1β into bone marrow cells treated with M-CSF and RANKL significantly increased TRAP-positive cells, resorption pit area, survival of osteoclast precursor cells, expression of c-Fos and NFATc1. Treatment of kaempferol reversed all these parameters in IL-1β-stimulated, RANKL-mediated bone marrow cells. The postulated mechanisms include the inhibition of intracellular MAPK, evidenced by decreased phosphorylation of ERK, p38 and c-Jun N-terminal kinase (JNK). In another study, more comprehensive mechanisms of the anti-inflammatory effects of kaempferol have been depicted. LPS triggered inflammation in murine macrophage RAW264.7 cells, whereby the production of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), NO, iNOS, IL-1β, TNF-α, MCP-1 and IL-6 were elevated. Treatment with resokaempferol exerted inhibitory effects on all these parameters, indicating its anti-inflammatory capacity. The molecular mechanisms involved were the activation (phosphorylation) of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 1 (STAT1), NF-κB and MAPK (including JNK and p38) following LPS stimulation, whereby the production of inflammatory mediators ensued. Resokaempferol alleviated inflammation by blocking the activation of these signaling pathways by LPS. In agreement with previous findings, kaempferol 7-O-β-D-glucoside (extracted from Cudrania tricuspidata) was capable of suppressing the expression of inflammatory mediators through inactivation (reduced phosphorylation).
High levels of ROS have been recognized as the pathogenic culprit in bone loss. The increased production of ROS elicits a spectrum of events that inhibit osteoblast differentiation and osteoclast apoptosis but induce osteoclast activity and osteoblast apoptosis. Hydrogen peroxide-induced oxidative stress causes a reduction in osteogenic markers ALP, COL1, BSP and Runx-2; thus inhibiting osteoblastic differentiation. Apart from that, ROS affects osteoblast lifespan by inducing apoptosis. The anti-oxidative effect of kaempferol was examined by Suh et al using MC3T3-E1 cells treated with 2-deoxy-D-ribose (dRib), a reducing sugar that produces ROS through the process of auto-oxidation and protein glycosylation resulting in osteoblast dysfunction. Kaempferol resulted in increased MC3T3-E1 cells growth, ALP activity, collagen content, mineralization and OPG secretion in the cells. Kaempferol also alleviated oxidative stress by reducing the malondialdehyde (MDA) contents in the dRib-treated MC3T3-E1 cells.

Despite its influence in the inhibition of osteoblast activity and function, ROS promotes osteoclastogenesis and inhibits osteoclast apoptosis through elevation of RANKL production in the osteoblastic lineage. The ROS-stimulated osteoclastogenesis has been shown to be mediated through multiple mechanisms, including the NF-κB and ERK signaling pathways. Kaempferol exerted potent inhibitory effects on in vitro bone resorption through alleviation of oxidative stress and induction of osteoclast apoptosis. Kaempferol inhibited bone resorption (evaluated by reduced resorption pit formation and hydroxylsylpyridinoline content) as well as inducing osteoclastic programmed cell death (evaluated by an increased number of apoptotic osteoclasts) in highly purified rabbit osteoclasts. Furthermore, kaempferol showed its anti-oxidative property by lowering the intracellular ROS production.

**Effects Of Kaempferol In Autophagy**

Autophagy, also known as autophagocytosis, is a major intracellular protein degradation pathway responsible for the removal of damaged cells in order to regenerate newer and healthier cells. There are four major steps involved in the process of autophagy, namely initiation/nucleation, elongation, maturation and degradation. In the initiation step, phagophore is formed facilitated by class III PI3K complex (consists of beclin-1, Vps34, Vps15, Ambra1 and UVRAG) as well as ULK1/ULK2. Herein, beclin-1 is the key autophagic regulator as it interacts with other co-factors to form the multiprotein complex. In the elongation step, phagophore is elongated forming an autophagosome facilitated by LC3II protein (converted from LC3I via lipidation process) and several autophagy-related genes (Atg). LC3II is recruited to the autophagosome’s membrane assisting the elongation and closure; therefore, it is fundamental in the formation of autophagosome. Typically, cytoplasmic components selected for degradation are tagged by p62/SQSTM1 (an autophagy receptor) and recognized by LC3II, which leads them to the interior of the autophagosome. In the final step, the fusion of autophagosomes with endosomes and lysosomes occurs, which is followed by the degradation of the autophagosome content. Thus, analyses of beclin-1, LC3II and p62/SQSTM1 are commonly used as the markers of autophagy.

Autophagy has been demonstrated to have a role in osteoblasts based on several considerations. Firstly, autophagy regulates bone cell survival and apoptosis which is important for the balance between bone formation and bone resorption. Secondly, autophagy potentially alleviates oxidative stress, a key factor for the progression of osteoporosis. Thirdly, the autophagy modulators such as calcium, vitamin D, resveratrol, estradiol and bisphosphonates have been reported to be beneficial to bone health. Hence, autophagy in osteoblasts is implicated in the process of osteoblast differentiation and mineralization to maintain bone homeostasis. A study by Kim et al verified that kaempferol at concentrations up to 10 μM increased ALP activity and expression of osteoblast-activated factors (including Runx-2, OSX, BMP-2 and COL1). Along with the enhancement of proliferation, differentiation and mineralization of osteoblastic MC3T3-E1 cells, kaempferol induced autophagosome formation by increasing the expression of the autophagy-related factors, beclin-1, sequestosome-1 (SQSTM1/p62) and the conversion of LC3-II from LC3-I.

Autophagy is also involved in modulating osteoclast formation and function. The increase in autophagy is associated with an increase in the viability of osteoclasts and bone resorption. Using a mouse model of systemic bone loss induced by glucocorticoids and ovariectomy, pharmacological and genetic inactivation of autophagy prevented bone loss by suppressing osteoclastogenesis and bone...
resorption in the animals. Mechanistically, it has been postulated that inhibition of autophagy lowers the secretion of cathepsin K thus disabling the differentiation and functional activity of osteoclasts. In a recent study, Kim et al revealed that kaempferol exhibited inhibitory effects on osteoclastogenesis (as shown by reduced TRAP-positive multinucleated cells, resorption pit formation, and expression of NFATc1, TRAF6 and c-Fos) as well as autophagy-related factors (as shown by decreased expression of beclin-1 and SQSTM1/p62) in RAW264.7 cells. In addition, the authors suggested that the inactivation of ERK and JNK was involved in the mechanism of action for kaempferol-inhibited autophagy in osteoclasts.

It is evident that kaempferol exerts differential effects on autophagy in osteoblast and osteoclast. Kaempferol activates autophagy in the bone-forming osteoblasts but inhibits autophagy in the bone-resorbing osteoclasts. Both actions favor the maintenance of bone homeostasis and prevention of bone loss.

Effects Of Kaempferol In Apoptosis

Apoptosis is a process of cell death mediated by caspase and B-cell lymphoma 2 (Bcl-2) family proteins through two distinct mechanisms, the extrinsic and intrinsic signaling pathways. The extrinsic pathway is activated by the binding of extracellular ligands to cell surface death receptors, including the interactions between Fas ligand (FasL)/Fas receptor (FasR), TNF-α/tumor necrosis factor receptor 1 (TNFR1) and TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor (TRAIL-R). The engagement between these best characterized ligands and receptors leads to the formation of death-inducing signaling complex (DISC), recruitment of Fas-associated death domain (FADD) adaptor and activation of initiator caspase-8. Subsequently, executioner caspase-3 is activated causing the dismantling of cellular components. The intracellular stress signals such as oxidative stress, endoplasmic reticulum stress, DNA damage and cytosolic calcium overload trigger the intrinsic pathway. The presence of internal stimuli causes disruption of mitochondrial outer membrane permeabilization (MOMP), governed by increased pro-apoptotic genes [Bcl-2-associated X protein (Bax)] and decreased anti-apoptotic gene (Bcl-2), resulting in the release of cytochrome c. Cytochrome c binds to apoptosis protease activating factor-1 (Apaf-1) and deoxyadenosine triphosphate (dATP) to form apoptosome complex. The apoptosome further activates caspase-9 and downstream caspase-3/6/7 to trigger apoptosis. The anti-apoptotic effects of kaempferol have been previously explored in osteoblasts. Using dexamethasone-induced rat calvarial osteoblasts, kaempferol caused a reduction in osteoblast apoptosis indicated by the stimulation of Bcl-2 expression and suppression of Bax expression. In this study, the postulated mechanism of action for the anti-apoptotic effects of kaempferol was elicited through the ERK signaling pathway. Western analysis results indicated that kaempferol amplified the phosphorylation of ERK.

Effects Of Kaempferol On Other Proteins

There are several other proteins that have been shown to implicate in the modulation of bone metabolism. Cytokeratin-14 and keratin-14 belongs to the cytoplasmic intermediate filament family and functions to self-assemble forming large bundles. Keratins are a group of tough and fibrous proteins providing structural framework of strength and resilience from mechanical and non-mechanical stress. HSP70 is a stress-inducible protein released in response to cellular stressors, such as heat shock, inflammation, fractures and infections. The osteogenic effects of HSP70 are accomplished through the enhancement of ALP activity, calcium deposition and upregulation of osteo-specific genes (Runx-2 and OSX) by activating the ERK signaling pathway. Aldose reductase is a key enzyme that catalyzes the conversion of glucose to sorbitol. A negative correlation between AR level and bone health has been reported. Galactose-induced diabetic rats had enhanced bone resorption and lower bone volume and osteoblast numbers, which were restored by the administration of epalrestat (an aldose reductase inhibitor). Caldesmon is known to participate in the regulation of actin cytoskeletal remodeling and alteration of cell surface adherence force, thereby facilitating the fusion of osteoclasts into multinucleated osteoclasts during osteoclastogenesis. Therefore, high levels of cytokeratin-14 and HSP-70 as well as low levels of AR and caldesmon might have a role in promoting osteoblast differentiation and inhibiting osteoclast differentiation.

In the presence of kaempferol, the rat calvarial osteoblasts had cuboidal morphology, developed intercellular networks, high ALP activity and increased mineralized nodules. Proteomic data revealed elevation of cytokeratin-14 and HSP70 but reduction of aldose reductase and caldesmon in rat calvarial osteoblasts treated with kaempferol. Another recent study further confirmed the role of cytokeratin-14 in osteoblast differentiation. The findings showed a positive relationship between cytokeratin-14 and matrix mineralization, which was corroborated by increased expression of...
cytokeratin-14, COL1 level, OCN level and collagen fiber density. It was surmised that the augmentation of cytokeratin-14 was involved in the regulation of osteoblast mineralization through reduction of phosphorylated adenosine monophosphate-activated protein kinase (AMPK) to activate the mammalian target of rapamycin complex 1 (mTORC1).^100^

**Conclusion And Future Directions**

Various doses of kaempferol have been tested in previous preclinical studies. Kaempferol may act as osteogenic and anti-osteostrogenic agent by acting on both osteoblasts and osteoclasts in a dose-dependent manner. In vivo studies also showed that higher dose of kaempferol increased callus diameter in the fractured mice, but this effect was not seen in the group treated with lower dose of kaempferol. Thus, it is postulated that higher dose of kaempferol conferred better protection on bone. However, the safety profile of kaempferol remains a major concern as researchers revealed signs of mutagenicity in the Ames test using *Salmonella typhimurium.* Based on the documented evidence, it is hypothesized that the possible underlying mechanisms for the anti-osteoporotic effects of kaempferol are in part mediated through (a) suppression of adipogenesis thus favoring osteoblastogenesis and chondrogenesis, (b) activation of estrogen receptor signaling pathway, (c) increase in Runx-2 expression that acts as the master of osteogenic transcription factor in BMP-2 signaling, (d) inhibition of inflammatory response through inhibition of NF-kB, (e) reduction of intracellular ROS production and lipid peroxidation, (f) differential regulation of autophagy in osteoblast and osteoclast, (g) suppression of osteoblast apoptosis as well as (h) regulation of proteins involved in osteoblast mineralization. All these molecular mechanisms play a relevant role in the maintenance of tightly coupled bone remodeling processes. The summary of the mechanisms of action that underlie the osteogenic property of kaempferol is illustrated in Figure 1.

Several limitations need to be addressed. Firstly, research on the effects of kaempferol on bone in humans is scarce but the results from in vivo and in vitro researches seem promising. Secondly, there is only a paucity of data indicating the anti-oxidative capacity of kaempferol using osteoblastic and osteoclastic cells. Thirdly, investigation on the effect of kaempferol on the antioxidant system is limited; particularly the levels of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and glutathione (GSH) were not evaluated. Fourthly, there is also a lack of scientific studies on the apoptotic activity of kaempferol in bone cells. By affecting both cell types (osteoblasts and osteoclasts) as well as bone cell communication, a multitude of redundant pathways (such as estrogen, BMP-2, MAPK and mTOR signaling mechanisms) and regulators (including cytokines and ROS) seem to be of major importance in bone cell function. This review reiterates that the design of potential agents targeting these major signaling cascades should be explored as the treatment for bone diseases. The growing evidence on the skeletal-protecting effects of kaempferol

---

**Figure 1** Summary of the mechanism of action involved in the osteoprotective effects of kaempferol.

**Abbreviations:** ACC, acetyl coenzyme A carboxylase; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; ALP, alkaline phosphatase; AMPK, adenosine monophosphate-activated protein kinase; AP-1, activator protein-1; AR, androgen receptor; AR, androgen receptor; ASH, adenylate kinase; ATG, autophagy-related gene; BMP, bone morphogenetic protein; COL, collagen; COX, cyclooxygenase; ER, estrogen receptor; ESR, estrogen-related receptor; FAS, fatty acid synthase; FGF, fibroblast growth factor; FoxO, forkhead box; GPx, glutathione peroxidase; HSP, heat shock protein; IL, interleukin; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; LPL, lipoprotein lipase; MAPK, mitogen-activated protein kinase; MCP, monocyte chemoattractant protein; MDA, malondialdehyde; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor-kappa B; OCN, osteocalcin; OPN, osteopontin; OSX, osteocalcin; PPAR-α, peroxisome proliferator-activated receptor-α; PPAR-γ, peroxisome proliferator-activated receptor-γ; RANKL, receptor activator of nuclear factor kappa-B ligand; ROS, reactive oxygen species; Runx-2, Runx-related transcription factor 2; SMAD, suppressor of mothers against decapentaplegic; SOX, SRY-box; TNF-α, tumor necrosis factor-α.

---

1. ACC, acetyl coenzyme A carboxylase.
2. ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs.
3. ALP, alkaline phosphatase.
4. AMPK, adenosine monophosphate-activated protein kinase.
5. AP-1, activator protein-1.
6. AR, androgen receptor.
7. ASH, adenylate kinase.
8. ATG, autophagy-related gene.
9. BMP, bone morphogenetic protein.
10. COL, collagen.
11. COX, cyclooxygenase.
12. ER, estrogen receptor.
13. ESR, estrogen-related receptor.
14. FAS, fatty acid synthase.
15. FGF, fibroblast growth factor.
16. FoxO, forkhead box.
17. GPx, glutathione peroxidase.
18. HSP, heat shock protein.
19. IL, interleukin.
20. JAK, Janus kinase.
21. JNK, c-Jun N-terminal kinase.
22. LPL, lipoprotein lipase.
23. MAPK, mitogen-activated protein kinase.
24. MCP, monocyte chemoattractant protein.
25. MDA, malondialdehyde.
26. MMP, matrix metalloproteinase.
27. mTOR, mammalian target of rapamycin.
28. NF-kB, nuclear factor-kappa B.
29. OCN, osteocalcin.
30. OPN, osteopontin.
31. OSX, osteocalcin.
32. PPAR-α, peroxisome proliferator-activated receptor-α.
33. PPAR-γ, peroxisome proliferator-activated receptor-γ.
34. RANKL, receptor activator of nuclear factor kappa-B ligand.
35. ROS, reactive oxygen species.
36. Runx-2, Runx-related transcription factor 2.
37. SMAD, suppressor of mothers against decapentaplegic.
38. SOX, SRY-box.
39. TNF-α, tumor necrosis factor-α.
supports its development as a potent adjunct for maintaining bone mass, skeletal integrity and preventing fractures. More importantly, the studies included in this review were performed in the in vivo and in vitro models. Further studies are warranted particularly in validating the clinical uses of kaempferol.

Acknowledgment
We thank Universiti Kebangsaan Malaysia for supporting this work via the MI-2019-006 and the FF-2019-036/1 grants.

Disclosure
The authors report no conflicts of interest in this work.

References


Dovepress


